View Older Stories

Apr 29, 2026 06:30AM Agios Pharma (AGIO) Tops Q1 EPS by 12c

Apr 21, 2026 08:48AM Agios Pharma (AGIO) PT Lowered to $41 at BofA Securities

Apr 21, 2026 06:41AM Agios Pharma (AGIO) PT Lowered to $50 at H.C. Wainwright

Apr 20, 2026 10:14AM Leerink Partners on Agios Pharma (AGIO): NVO's Ph3 trial results likely to pressure shares

Mar 31, 2026 01:08PM Leerink on Fulcrum Therapeutics (FULC): 'We believe this is a positive sign for FULC'

Mar 31, 2026 09:48AM Agios Pharma (AGIO) PT Raised to $44 at BofA Securities

Mar 31, 2026 08:54AM Stifel: 'we think FULC as a soon-to-be ph3 SCD company is significantly under-appreciated'

Mar 31, 2026 08:33AM Truist Securities stays Buy on Agios Pharma (AGIO) as co seeks accelerated approval for mitapivat

Mar 12, 2026 09:27AM Agios Pharma (AGIO): 'Aqvesme's opportunity in thalassemia reason enough to own the stock,' says analyst

Mar 5, 2026 06:40AM Agios Pharma (AGIO) PT Raised to $46 at Citi, Opens Catalyst Watch

Feb 12, 2026 04:22PM Agios Pharma (AGIO) files mixed shelf

Feb 12, 2026 11:40AM Agios Pharma (AGIO) PT Raised to $39 at Truist Securities

Jan 12, 2026 07:03AM Agios outlines 2026 milestones for rare disease drug portfolio

Dec 26, 2025 08:15AM Agios Pharma (AGIO) removed from Upside 30-Day Catalyst Watch at Citi

Dec 26, 2025 07:01AM Agios Pharma (AGIO) PT Raised to $34 at BofA Securities

Dec 24, 2025 12:28PM Agios Pharma (AGIO) PT Raised to $62 at H.C. Wainwright

Dec 9, 2025 06:56AM H.C. Wainwright Reiterates Buy Rating on Agios Pharma (AGIO)

Dec 8, 2025 07:02AM Agios awaits FDA decision on mitapivat for thalassemia treatment

Nov 25, 2025 07:31AM Agios Pharma (AGIO) Management Sees a Path to Profitability - Cantor Fitzgerald

Nov 25, 2025 07:09AM Citi Opens 30-Day Positive Catalyst Watch on Agios Pharma (AGIO)

Nov 25, 2025 06:59AM Citi Starts Agios Pharma (AGIO) at Buy, PT $38

Nov 24, 2025 07:36AM Truist Securities Starts Agios Pharma (AGIO) at Buy

Nov 20, 2025 07:51AM Agios Pharma's (AGIO) Regulatory Path in the Air - Cantor Fitzgerald

Nov 20, 2025 06:38AM Agios Pharma (AGIO) PT Lowered to $48 at H.C. Wainwright

Nov 20, 2025 06:19AM Leerink Partners Upgrades Agios Pharma (AGIO) to Outperform

Nov 19, 2025 03:04PM Agios Pharma (AGIO) call put ratio 1 call to 1.2 puts with a focus on January 22.50 puts and January 45 calls

Nov 19, 2025 01:53PM Agios Pharma (AGIO) PT Lowered to $32 at BofA Securities

Nov 19, 2025 12:44PM RBC Capital Downgrades Agios Pharma (AGIO) to Sector Perform

Oct 30, 2025 06:30AM Agios Pharma (AGIO) Tops Q3 EPS by 12c

Oct 20, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Agios Pharma (AGIO)

Oct 17, 2025 08:15AM CHMP recommends PYRUKYND approval for adults with thalassemia

Oct 17, 2025 08:01AM Agios' PYRUKYND receives positive European opinion for thalassemia

Oct 16, 2025 04:45AM Increasing unusual option volume: HOND TMQ UROY WWR TTI AGIO GTES

Sep 24, 2025 03:10PM SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Agios Pharmaceuticals, Inc. (AGIO) and Encourages Long-Term Investors to Contact the Firm

Sep 5, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Agios Pharma (AGIO)

Sep 5, 2025 05:02AM Goldman Sachs on Agios Pharma (AGIO): 'we see a favorable risk-benefit profile'

Sep 4, 2025 12:08PM TD Cowen on Agios Pharma (AGIO): 'we view an extension rather than issuance of a CRL as a positive sign'

Sep 4, 2025 10:23AM Agios Pharma (AGIO) PT Lowered to $51 at BofA Securities

Sep 4, 2025 07:00AM FDA extends PYRUKYND review date to December for thalassemia treatment

Aug 5, 2025 09:07AM TD Cowen on Agios Pharma (AGIO): 'Per Usual FAERS Mislead; AGIO Remains Our Top Pick'

Aug 5, 2025 06:34AM Agios Pharma (AGIO) PT Raised to $52 at BofA Securities

Aug 4, 2025 04:01PM Agios' PYRUKYND approved for thalassemia treatment in Saudi Arabia

Aug 4, 2025 01:59PM Agios addresses analyst report on PYRUKYND safety data

Jul 31, 2025 06:31AM Agios Pharma (AGIO) Misses Q2 EPS by 12c

Jul 8, 2025 07:00AM Agios Pharmaceuticals adds Dr. Jay Backstrom to board of directors

Jun 16, 2025 09:36AM TD Cowen Names Agios Pharma (AGIO) 'Best Smidcap Idea'

Jun 10, 2025 06:37AM Agios Pharma (AGIO) PT Lowered to $56 at H.C. Wainwright

Jun 9, 2025 08:41AM Avanzanite Bioscience Announces Pan-European Partnership with Agios to Launch PYRUKYND in Rare Blood Disorders

May 25, 2025 03:00PM Biotech stocks Q1 earnings review

May 13, 2025 07:36AM Cantor Fitzgerald Reiterates Overweight Rating on Agios Pharma (AGIO)

View Older Stories